IC

ImmuCell CorpNASDAQ ICCC Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

0.028

Micro

Exchange

XNAS - Nasdaq

ICCC Stock Analysis

IC

Uncovered

ImmuCell Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-22/100

Low score

Market cap $B

0.028

Dividend yield

Shares outstanding

7.747 B

ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.

View Section: Eyestock Rating